Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Independent Technical Report

25 Jul 2012 07:00

RNS Number : 4221I
Fastnet Oil & Gas PLC
25 July 2012
 



25 July 2012

Fastnet Oil & Gas plc

Publication of Independent Technical Report

 

Fastnet Oil and Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the newly listed E&P company focussed on near term exploration acreage in the Celtic Sea and Africa, is pleased to announce the publication of independent technical reports by SLR Consulting (the "Technical Reports") on the Molly Malone Basin and Mizzen Basin.

 

Highlights

·; Total best case unrisked in-place resource estimates for:

o The Mizzen Basin is approximately 2.4 billion boe (oil case) or 957 MMboe (gas case)

o The Molly Malone Basin is approximately 12.5 billion bbl (oil case) or 3.6 billion boe (gas case)

·; Technical Reports corroborate the Company's estimates stated on Admission

·; The reserves potential outlined in the Technical Reports fits with the Company's strategy of targeting high impact licences that are likely to be attractive to oil industry majors

·; Outline of a seismic re-processing programme in order to de-risk and mature prospects within the licence areas

·; Confirms the significant opportunity presented by the currently under explored Molly and Mizzen Basins

·; On completion of the work programmes, in line with the Board's strategy, both the Molly and Mizzen Basins could present a high impact opportunity to potential major industry players

 

Table of independent technical estimates

 

 

Mizzen Basin

Trap

Unrisked in-place resource estimates

GPoS

Main risk

Low

Best

High

Wealden Oil (MMbbl)

571.2

1,799.3

3,898.5

4%

Source

Wealden Gas (BCF)

658.6

2,074.7

4,723.6

12%

Seal

Triassic Gas (BCF)

1,473.7

3,108.2

9,355.9

5%

Seal & migration

 

Molly Malone Basin

Trap

Unrisked in-place resource estimates - Best estimate

GPoS

Main risk

North prospect Gas (BCF)

10,448.4

12%

Maturity

South Prospect Gas (BCF)

9,127.9

8%

Maturity

North Prospect Oil (MMbbl)

6,677.3

9%

Migration

South Prospect Oil (MMbbl)

5,833.4

5%

Migration

\* The seismic quality and wide spacing precludes production of High and Low estimates for Molly Malone (Source: SLR).

 

Key: GPoS = geological probability of success; BCF = billion cubic feet of gas, MMbbl = million barrels of oil. 1,000ft3 of gas is equivalent to 0.1847 barrels of oil (source: Wood MacKenzie).

 

The Technical Reports validate the Company's strategy set out at the time of IPO in June 2012 of the resource potential in its Molly and Mizzen licencing options. The resource estimates are large, however the geological probability of success figures are at a level which requires the Company to undertake a significant work program to mature the prospects in order to de-risk and identify drill ready targets.

 

Celtic Sea licence area work programme

 

Molly Malone Basin

The basin is located within the Celtic Sea Basin in water depths of up to 100 metres. The licensing option covers block 50/26 and part blocks 49/25, 49/30, 50/21 and 50/22 in the North Celtic Sea basin.

The Company plans to undertake seismic reprocessing of the 180 kilometres of existing 2D seismic data, subject to locating, accessing and copying the original seismic field tapes. It should be noted that the 1984 survey is fairly widely spaced and even with good results, this reprocessing can only help to define possible plays and assist in the design of a 3D seismic survey that would add valuable information prior to drilling.

 

Thick salt has developed over parts of the Molly Malone Basin which obscures the mapping of the prospective Triassic Sherwood Sands over the north-eastern part of the dominant structural lead mapped within the Molly Malone Basin. Pre-stack depth migration will assist in defining fault plane and Sherwood Sand reservoir geometry beneath the salt.

 

The Board is of the view that it is essential to improve the understanding of the nature of the stratigraphic section beneath the Triassic salt in the Molly Malone Basin, through the application of modern seismic reprocessing techniques and carrying out a programme of regional studies in order to design the appropriate acquisition parameters for any potential 3D seismic survey. Additionally, further analysis of the existing seismic data is needed to examine the potential for north-eastern closure for the dominant prospective lead in the Molly Malone Basin before a significant financial commitment to a 3D seismic survey can be made.

 

Mizzen Basin

This basin is located within the Celtic Sea Basin in water depths of up to 160 metres. The licensing option covers blocks 55/14 and 55/15 and part blocks 55/9 and 55/10 in the South Celtic Sea basin.

Fastnet intends to reprocess a minimum of 550 kilometres of existing 2D seismic data, subject to locating, accessing and copying seismic field tapes.

 

Sub-Chalk interbed multiple content is a particular issue in parts of the Mizzen Basin which obscures the presence of unconformities; reduces the level of confidence with respect to picking stratigraphic markers due to an inability to identify velocity breaks; hampers correlation across faults; and prevents detailed stratigraphic analysis of potential seismic sequence geometries and reconnaissance amplitude mapping. Pre-stack depth migration could potentially assist defining the complex fault plane traces seen on existing seismic data; better identify potential discordant igneous intrusions; and better resolve subcrop relationships and significant unconformities where steeply dipping seismic events terminate at specific levels within the stratigraphic sequences.

 

The Board is of the view that it is essential to improve the understanding of the nature of the stratigraphic section in the Mizzen Basin through the application of modern seismic reprocessing techniques and carrying out a programme of regional studies, in order to design the appropriate acquisition parameters for any potential future 3D seismic survey to be acquired.

 

Design of 3D Seismic Survey

Subject to satisfactory results from the 2D seismic processing, a 3D seismic survey will be designed and appropriate acquisition parameters put in place to reflect the depth and nature of the primary prospective horizons present in the Molly Malone Basin and Mizzen Basin.

 

Working Capital

The funding requirement for Fastnet arising during the initial 18 month licence options in respect of proposed work programmes for the Molly Malone and Mizzen Basin is expected to be approximately £0.5 million.

 

Dr.Steve Staley, CEO of Fastnet commented:

 "I am very pleased to announce the publication of these independent technical reports on our Celtic Sea licences. The findings confirm our own initial estimates of the potential resource estimates that we published in our IPO prospectus in June 2012. They concur with our strategy of targeting and acquiring large scale, high impact acreage, in areas well known to our technical team which are of likely interest to other industry partners.

 

"The Barryroe discovery in the Celtic Sea, close to our acreage, has proven large scale commercial oil finds exist in the Celtic Sea and through the Mizzen Basin and Molly Malone Basin, we are confident that substantial reservoir structures exist. Some members of the Fastnet team, including Paul Griffiths, carried out exploratory work on the Mizzen Basin in the early 1990's and they believe it is one of the greatest unexplored structures in the Celtic Sea. The Molly Malone Basin has had little to no exploration to date, as for decades it sat adjacent to the international median boundary line between the UK and Ireland, which has only recently been clarified; giving Fastnet a huge opportunity.

 

"We look forward to progressing the work programmes across the licence area, as we seek to mature the prospects to drill ready status and I look forward to updating shareholders on developments as appropriate."

 

- Ends -

 

 

 

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Non-Executive Chairman

Steve Staley, CEO

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Billy Clegg

Edward Westropp

+44 (0) 207 831 3113

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCRIMBTMBBTTLT
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.